{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-190873","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2022-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.891191+00:00","generated_at":"2026-06-24T17:36:51.888317+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved","bullets":["INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.","Pooled PLN-74809 showed 80% reduction in FVC decline vs placebo (-15.1 mL vs -74.1 mL); 80 mg dose showed +24.6 mL FVC increase from baseline.","Dose-dependent reduction in ≥10% FVCpp decline: 18.2% (40mg), 8.7% (80mg), 4.5% (160mg) vs 17.4% placebo.","QLF imaging showed dose-dependent antifibrotic effect; 160 mg group showed 0.00% mean change vs 1.15% placebo.","Company to discuss data with regulators; 320 mg cohort data expected early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-190873","json":"https://secwatch.observer/filing/0001193125-22-190873.json","markdown":"https://secwatch.observer/filing/0001193125-22-190873.md","text":"https://secwatch.observer/filing/0001193125-22-190873.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/0001193125-22-190873-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/d356984d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T17:36:51.888317+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}